BUFFALO, NY--(Marketwired - August 07, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2014.
Cleveland BioLabs reported a net loss for the second quarter of 2014 of $4.0 million, or $0.08 per share, compared to a net loss of $3.0 million, or $0.07 per share, for the same period in 2013. Net loss for the first six months of 2014 was $5.5 million, or $0.11 per share, compared to a net loss of $12.8 million, or $0.29 per share, for the same period in 2013. $3.1 million of the improvement in net loss for the six-month period was due to a non-cash change in the fair market valuation of certain outstanding warrants, with the remaining $4.2 million of this improvement, due to a reduction in operating losses. The reduced operating losses were due to a narrowed focus of development activities, lower development costs for entolimod's biodefense indication and other cost saving measures.
At June 30, 2014, the Company had cash, cash equivalents and short-term investments of $11.1 million, $7.7 million of which was available for general use and $3.4 million of which was restricted for the use of majority-owned subsidiaries.
Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "We are making progress towards achievement of our operational objectives for 2014. We are encouraged by the tone and direction of our recent meeting with the U.S. Food and Drug Administration to review dose conversion and evaluate the potential for a pre-emergency use authorization (pre-EUA) submission for entolimod's biodefense indication. We look forward to sharing more details regarding the meeting's outcomes and next steps once we have received and reviewed the official meeting minutes. Our oncology trials continue to advance, as well. We are analyzing interim data for the oral administration study of our lead oncology drug candidate, Curaxin CBL0137 and compiling data on immune cell response to administrations of entolimod in the ongoing advanced cancer study. Finally, we are anticipating the opening of an Investigational New Drug (IND) Application in the Russian Federation shortly for a healthy subject study supported by a contract with the Ministry of Industry and Trade of the Russian Federation for CBLB612, a drug candidate in development for the induction and mobilization of hematopoietic stem cells."
Operational Highlights
The Phase 1 study of entolimod in patients with advanced cancer at Roswell Park Cancer Institute continues.
Dosing of the fourth cohort is well underway in a multi-center, Phase 1 trial assessing the intravenous administration of Curaxin CBL0137 in patients with metastatic or unresectable advanced solid cancers and lymphomas. In parallel, dosing of the seventh cohort continues in a multicenter, Phase 1 study assessing the oral administration of Curaxin CBL0137 in patients with advanced solid tumors that are resistant or refractory to current standard treatment.
To date, no drug-related serious adverse events have been reported in any of the mentioned trials.
Further Financial Highlights
Revenue for the second quarter of 2014 decreased to $0.6 million compared to $1.6 million for the second quarter of 2013. Revenue for the first six months of 2014 decreased to $1.9 million compared to $3.0 million for the same period in 2013. These decreases were primarily the result of the completion of certain contracts with the Department of Defense for entolimod's biodefense indication and changes in other contracts with the Ministry of Industry and Trade of the Russian Federation, or MPT.
Research and development costs for the second quarter of 2014 decreased to $2.3 million compared to $5.4 million for the same period in 2013. Six-month research and development costs for the 2014 period decreased to $4.8 million compared to $10.7 million for the same period in 2013. These decreases were primarily due to completion of third-party service contracts for several compounds, as well as reduced compensation costs primarily attributable to our transfer of personnel to Buffalo BioLabs, LLC in the fourth quarter of 2013.
General and administrative costs for the second quarter of 2014 decreased to $2.3 million compared to $3.0 million for the same period in 2013. General and administrative costs for the first six months of 2014 decreased to $4.7 million compared to $6.5 million for the same period in 2013. For the second quarter, these decreases were wholly due to a reduction of personnel. For the six-month period, $1.2 million of these decreases were due to a reduction of personnel and $0.6 million were due to other cost-saving actions.
Conference Call Information
Cleveland BioLabs management will host a conference call at 10:00 a.m. ET today to provide updates and address investor questions regarding general business developments. Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs web site at www.cbiolabs.com. A replay of the call will be available starting on August 7, 2014, at 1:00 p.m. ET through August 24, 2014, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13586610. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs web site at www.cbiolabs.com.
About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are entolimod, which is being developed for a biodefense indication and as a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.
This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "making progress," "encouraged," "look forward," "continue to advance" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; the conduct and results of our various clinical trials; our ability to obtain approval from the U.S. Food and Drug Administration of our product candidates; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include, among others, the Company's failure to successfully and timely develop existing and new products; the Company's collaborative relationships and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's ability to comply with its obligations under license agreements; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
June 30, December 31,
2014 2013
------------ ------------
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 11,103,596 $ 10,048,466
Short-term investments - 305,538
Accounts receivable 392,696 458,391
Other current assets 477,339 344,386
------------ ------------
Total current assets 11,973,631 11,156,781
Equipment, net 335,230 457,912
Restricted cash 2,843,413 2,921,724
Other long-term assets 74,663 159,224
------------ ------------
Total assets $ 15,226,937 $ 14,695,641
============ ============
LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 719,637 $ 794,397
Accrued expenses 2,122,690 2,445,446
Deferred revenue 744,500 1,069,438
Accrued warrant liability 1,024,720 1,241,311
Current portion of note payable 481,903 351,527
Current portion of capital lease obligation 50,827 83,634
------------ ------------
Total current liabilities 5,144,277 5,985,753
Noncurrent portion of capital lease obligation - 7,522
Long-term debt 3,634,034 7,121,388
Commitments and contingencies - -
------------ ------------
Total liabilities 8,778,311 13,114,663
Stockholders' equity:
Total Cleveland BioLabs, Inc. stockholders'
deficit (6,387,894) (9,522,945)
Noncontrolling interest in stockholders'
equity 12,836,520 11,103,923
------------ ------------
Total stockholders' equity 6,448,626 1,580,978
------------ ------------
Total liabilities and stockholders' equity $ 15,226,937 $ 14,695,641
============ ============
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Quarter Ended June 30, Six months ended June 30,
2014 2013 2014 2013
------------ ------------ ------------ ------------
Revenues:
Grants and
contracts $ 562,087 $ 1,613,262 $ 1,896,341 $ 2,980,734
Operating expenses:
Research and
development 2,324,223 5,373,029 4,763,996 10,704,644
General and
administrative 2,250,368 3,016,851 4,663,911 6,500,223
------------ ------------ ------------ ------------
Total operating
expenses 4,574,591 8,389,880 9,427,907 17,204,867
------------ ------------ ------------ ------------
Loss from operations (4,012,504) (6,776,618) (7,531,566) (14,224,133)
------------ ------------ ------------ ------------
Other income
(expense):
Interest and other
income (expense) (623,786) 47,809 (941,708) 127,765
Foreign exchange
gain (loss) 92,594 46,776 (59,177) 74,910
Change in value of
warrant liability 412,125 2,795,612 2,499,683 (652,111)
------------ ------------ ------------ ------------
Total other
income
(expense) (119,067) 2,890,197 1,498,798 (449,436)
------------ ------------ ------------ ------------
Net loss (4,131,571) (3,886,421) (6,032,768) (14,673,569)
Net loss
attributable to
noncontrolling
interests 170,410 844,310 486,235 1,867,135
------------ ------------ ------------ ------------
Net loss
attributable to
Cleveland BioLabs,
Inc. $ (3,961,161) $ (3,042,111) $ (5,546,533) $(12,806,434)
============ ============ ============ ============
Net loss available
to common
stockholders per
share of common
stock, basic and
diluted $ (0.08) $ (0.07) $ (0.11) $ (0.29)
============ ============ ============ ============
Weighted average
number of shares
used in calculating
net loss per share,
basic and diluted 51,891,629 44,948,591 50,935,194 44,887,920
============ ============ ============ ============
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six months ended June 30,
2014 2013
------------- -------------
Cash flows used in operating activities $ (7,726,002) $ (14,123,795)
Cash flows provided by investing activities 275,078 2,171,034
Cash flows provided by (used in) financing
activities 8,572,411 (28,176)
Effect of exchange rate change on cash and
equivalents (69,292) (425,749)
------------- -------------
Increase (decrease) in cash and cash
equivalents 1,052,195 (12,406,686)
Cash and cash equivalents at beginning of
period 10,048,466 25,652,083
------------- -------------
Cash and cash equivalents at end of period $ 11,100,661 $ 13,245,397
============= =============
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES
NON-GAAP FINANCIAL MEASURES
(UNAUDITED)
We define net cash burn as the net increase (or decrease) in cash, cash
equivalents and short-term investments excluding the effect of capital
markets financing activities, and the net increase (or decrease) in
restricted cash, as determined in accordance with generally accepted
accounting principles or GAAP. And we separately track net cash burn for
Cleveland BioLabs, Inc. and its wholly-owned subsidiary BioLab 612, LLC,
which we refer to as CBLI Stand-alone, as well as for the consolidated
entity which includes the accounts of Incuron, LLC, Panacela Labs, Inc. and
Panacela Labs, LLC. This non-GAAP measure may be considered in addition to
results prepared in accordance with GAAP, but should not be considered a
substitute for, or superior to, GAAP results. We believe that net cash burn
is relevant and useful information for the Company and our investors as it
provides a simple method of determining net cash used by the Company. A
calculation of net cash burn is provided below:
Quarter Ended June 30, Six months Ended June 30,
2014 2013 2014 2013
------------ ------------ ------------ ------------
CBLI Stand-alone:
Cash, cash
equivalents, and
short-term
investments,
beginning of
period $ 12,021,569 $ 13,333,966 $ 7,957,302 $ 17,945,147
Cash, cash
equivalents and
short-term
investments, end
of period 7,654,233 8,789,689 7,654,233 8,789,689
------------ ------------ ------------ ------------
Period decrease (4,367,336) (4,544,277) (303,069) (9,155,458)
Plus repayment of
long-term debt 4,000,000 - 4,000,000 -
Less net proceeds
from the sale of
common stock (3,342,500) - (9,697,501) -
------------ ------------ ------------ ------------
Net operating cash
burn for the
period (3,709,836) (4,544,277) (6,000,570) (9,155,458)
Number of months
in period 3 3 6 6
------------ ------------ ------------ ------------
Net monthly
operating cash
burn $ (1,236,612) $ (1,514,759) $ (1,000,095) $ (1,525,910)
============ ============ ============ ============
Consolidated:
Cash, cash
equivalents, and
short-term
investments,
beginning of
period $ 13,671,910 $ 21,055,874 $ 10,354,004 $ 28,286,027
Cash, cash
equivalents and
short-term
investments, end
of period 11,103,596 13,551,123 11,103,596 13,551,123
------------ ------------ ------------ ------------
Period
increase/
(decrease) (2,568,314) (7,504,751) 749,592 (14,734,904)
Plus repayment of
long-term debt 4,000,000 - 4,000,000 -
Less
noncontrolling
interest capital
contribution to
Incuron, LLC (2,915,239) - (2,915,239) -
Less net proceeds
from the sale of
common stock (3,342,500) - (9,697,501) -
------------ ------------ ------------ ------------
Net operating cash
burn for the
period (4,826,053) (7,504,751) (7,863,148) (14,734,904)
Number of months
in period 3 3 6 6
------------ ------------ ------------ ------------
Net monthly
operating cash
burn $ (1,608,684) $ (2,501,584) $ (1,310,525) $ (2,455,817)
============ ============ ============ ============
Contact:
Rachel Levine
Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (917) 375-2935
E: rlevine@cbiolabs.com
Help employers find you! Check out all the jobs and post your resume.
